For the first time, a systemic therapy has shown efficacy in a rare form of melanoma that affects the eye, uveal melanoma. New data showing activity with the investigational drug selumetinib, an MEK inhibitor under development by AstraZeneca, was hailed as a research "breakthrough" here at the 2013 Annual Meeting of the American Society of Clinical Oncology. Uveal melanoma is one of the most difficult cancers to treat," commented ASCO spokesperson and melanoma expert Lynn Schechter, MD, from the Abramson Cancer Center in Philadelphia, Pennsylvania. This is the first clinical trial to identify a drug that improves clinical outcomes in advanced disease, she commented: "This represents a first real advance for these patients." To see more details visit, www.medscape.com/